Literature DB >> 19344438

Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.

Caleb J Banta-Green1, Charles Maynard, Thomas D Koepsell, Elizabeth A Wells, Dennis M Donovan.   

Abstract

AIMS: To assess retention in methadone maintenance treatment for prescription-type opioid primary (PTOP) users compared to heroin users. DESIGN AND PARTICIPANTS: A retrospective cohort study was carried out to examine the association between opiate types used on 12-month retention. The study population consisted of adults admitted to one of 11 not-for-profit methadone maintenance clinics in 2004 and 2005 throughout Washington State (n = 2308). Logistic regression analyses with fixed effects for treatment agencies were conducted. MEASUREMENTS: Opiate use type in past 30 days: any heroin use or primary prescription opioid without heroin use. Demographics, other drugs used, self-reported medical and psychiatric concerns, social, familial and legal issues, public assistance type and housing stability were documented at intake using a comprehensive biopsychosocial instrument, the Treatment and Assessment Reports Generation Tool.
FINDINGS: The odds of being retained in treatment for PTOP compared to heroin users not adjusting for other factors was 1.33 (95% confidence interval [CI], 1.03, 1.71). In the final logistic regression model the odds of retention for PTOP compared to heroin users was 1.25 (95% CI, 0.93, 1.67), indicating that there was no statistically significant difference in treatment retention by opiate type after adjusting for demographics, treatment agencies, other drug use, public assistance type, medical, psychiatric, social, legal and familial factors.
CONCLUSION: The findings of this study suggest that PTOP can be treated at methadone maintenance treatment facilities at least as effectively as heroin users in terms of treatment retention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344438     DOI: 10.1111/j.1360-0443.2009.02538.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  23 in total

1.  Profiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United States.

Authors:  Marcus A Bachhuber; William N Southern; Chinazo O Cunningham
Journal:  Med Care       Date:  2014-05       Impact factor: 2.983

2.  Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment.

Authors:  Brent A Moore; David A Fiellin; Christopher J Cutter; Frank D Buono; Declan T Barry; Lynn E Fiellin; Patrick G O'Connor; Richard S Schottenfeld
Journal:  J Subst Abuse Treat       Date:  2016-09-02

3.  How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Li-Tzy Wu; George E Woody; Chongming Yang; Dan G Blazer
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

4.  Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).

Authors:  Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling
Journal:  J Stud Alcohol Drugs       Date:  2013-07       Impact factor: 2.582

5.  A method to diagnose opioid dependence resulting from heroin versus prescription opioids using the Composite International Diagnostic Interview.

Authors:  Jennifer S Potter; Kristi Prather; Frankie Kropp; Mimmie Byrne; C Rollynn Sullivan; Nadia Mohamedi; Marc L Copersino; Roger D Weiss
Journal:  Contemp Clin Trials       Date:  2010-01-14       Impact factor: 2.226

6.  Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints.

Authors:  Katherine M Sharkey; Megan E Kurth; Bradley J Anderson; Richard P Corso; Richard P Millman; Michael D Stein
Journal:  Drug Alcohol Depend       Date:  2010-01-15       Impact factor: 4.492

7.  Engagement, retention, and abstinence for three types of opioid users in Florida.

Authors:  Brian E McCabe; Daniel A Santisteban; Maite P Mena; Darran M Duchene; Carali McLean; Marcia Monroe
Journal:  Subst Use Misuse       Date:  2013-06-10       Impact factor: 2.164

8.  Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States.

Authors:  Phillip L Marotta; Kristi L Stringer; Amar D Mandavia; Alissa Davis; Leo Beletsky; Tim Hunt; Dawn Goddard-Eckrich; Elwin Wu; Louisa Gilbert; Nabila El-Bassel
Journal:  J Addict Dis       Date:  2019-12-10

9.  Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.

Authors:  C J Banta-Green; J R Williams; J M Sears; A S Floyd; J I Tsui; T J Hoeft
Journal:  Drug Alcohol Depend       Date:  2019-12-11       Impact factor: 4.492

10.  Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.

Authors:  Iuliia Makarenko; Alyona Mazhnaya; Ruthanne Marcus; Iryna Pykalo; Lynn Madden; Sergii Filippovich; Sergii Dvoriak; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2018-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.